Mechanism, prevention, risk assessment and treatment in bisphosphonates induced osteonecrosis of the jaw |
Park, Jung-Chul
(Department of Periodontology, Research Institute of Periodontal Regeneration, College of Dentistry, Yonsei University)
Jung, Ui-Won (Department of Periodontology, Research Institute of Periodontal Regeneration, College of Dentistry, Yonsei University) Kim, Chang-Sung (Department of Periodontology, Research Institute of Periodontal Regeneration, College of Dentistry, Yonsei University) Cho, Kyoo-Sung (Department of Periodontology, Research Institute of Periodontal Regeneration, College of Dentistry, Yonsei University) Chai, Jung-Kiu (Department of Periodontology, Research Institute of Periodontal Regeneration, College of Dentistry, Yonsei University) Kim, Chong-Kwan (Department of Periodontology, Research Institute of Periodontal Regeneration, College of Dentistry, Yonsei University) Choi, Seong-Ho (Department of Periodontology, Research Institute of Periodontal Regeneration, College of Dentistry, Yonsei University) |
1 | Epstein S. Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Clin Ther 2006; 28:151-173 DOI PUBMED ScienceOn |
2 | Fleisch H, Russell RG, Straumann F. Effect of pyrophosphateon hydroxyapatite and its implications in calcium homeostasis. Nature 1966;212:901-903 DOI ScienceOn |
3 | Rogers MJ, Gordon S, Benford HL, et aL Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000;88:2961-2978 DOI PUBMED ScienceOn |
4 | Dixon R, Tricker N, Garetto L. Bone turnover in elderly canine mandibles and tibia. J Dent Res 76(IADR Abstracts) 1997:2579 |
5 | Jeffcoat MK. Safety of oral bisphosphonates: controlled studies on alveolar bone. Int J Oral Maxillofac Implants 2006;21 :349-353 PUBMED |
6 | IMS, HEALTH. NPA Plus May, 2006. |
7 | American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369-376 DOI PUBMED ScienceOn |
8 | Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002;4:30-4 DOI PUBMED |
9 | Marx RE. Pamidronate(Aredia) and zoledronate(Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-1117 DOI ScienceOn |
10 | Bergstrom JD, Bostedor RG, Masarachia PJ, et a!. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 2000;373: 231-241 DOI ScienceOn |
11 | Benford HL, Frith JC, Auriola S, et aL Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 1999;56: 131-140 DOI PUBMED |
12 | Bilezikian JP. Osteonecrosis of the jaw--do bisphosphonates pose a risk? N Engl J Med 2006;355:2278-2281 DOI ScienceOn |
13 | Hansen T, Kunkel M, Weber A, James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 2006;35: 155-160 DOI ScienceOn |
14 | Walter C, Grotz KA, Kunkel M, Al-Nawas B. Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer 2007;15: 197-202 DOI ScienceOn |
15 | McClung MR. Bisphosphonates. Endocrinol Metab Clin North Am 2003;32:253-271 DOI ScienceOn |
16 | Rosen HN, Moses AC, Garber J, et al. Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 2000;66:100-3 DOI ScienceOn |
17 | Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580-8587 DOI ScienceOn |
18 | Sedghizadeh PP, Stanley K, Caligiuri M, et al. Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry. J Am Dent Assoc 2009; 140:61-66 DOI PUBMED |
19 | Grbic JT, Landesberg R, Lin SQ, et al. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc 2008;139:32-40 DOI PUBMED |
20 | Berenson JR, Hillner BE, Kyle RA, et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002;20:3719-3736 DOI ScienceOn |
21 | Ficarra G, Beninati F, Rubino I, et a!. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol 2005;32: 1123-8 DOI ScienceOn |
22 | Migliorati CA. Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol 2003;21 :4253-4254 DOI ScienceOn |
23 | Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65:415-423 DOI ScienceOn |
24 | Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002;62:6538-6544 PUBMED |
25 | Bagan lV, Jimenez Y, Murillo J, et aL Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral Oneol 2006;42:327-329 DOI ScienceOn |
26 | Schwartz IE. Ask us: Some drugs affect tooth movement. Am J Orthod Dentofacial Orthop 2005;127:644 DOI ScienceOn |
27 | Vignery A, Baron R. Dynamic histomorphometry of alveolar bone remodeling in the adult rat. Anat Rec 1980; 196: 191-200 |
28 | Edwards BJ, Hellstein JW, Jacobsen PL, et aL Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 2008;139:1674-1677 DOI PUBMED |
29 | Brunski JB. In vivo bone response to biomechanical loading at the bone/dental-implant interface. Adv Dent Res 1999; 13:99-119 DOI ScienceOn |
30 | Friberg B, Ekestubbe A, Mellstrom D, Sennerby L. Branemark implants and osteoporosis: a clinical exploratory study. Clin Implant Dent Relat Res 2001;3:50-56 DOI ScienceOn |
31 | Wang HL, Weber D, McCauley LK. Effect of long-term oral bisphosphonates on implant wound healing: literature review and a case report. J Periodontol 2007;78:584-594 DOI ScienceOn |
32 | Owens G, Jackson R, Lewiecki EM. An integrated approach: bisphosphonate management for the treatment of osteoporosis. Am J Manag Care 2007;13 Suppl 11:S290-308; quiz S309-312 PUBMED |
33 | Black DM, Delmas PD, Eastell R, et al. Once-yearly zole-dronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-1822 DOI ScienceOn |
34 | Lehenkari PP, Kellinsalmi M, Napankangas JP, et a!. Further insight into mechanism of action of clodronate: 111- hibition of mitochondrial ADP/ATP translocasc by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol 2002;61 :1255-1262 DOI ScienceOn |
35 | Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-761 DOI PUBMED ScienceOn |
36 | Boonyapakom T, Schirmer I, Reichart PA, et al. Bisphosphonateinduced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 2008;44:857-869 DOI ScienceOn |
37 | Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-1575 DOI ScienceOn |
38 | Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006;24:945-952 DOI ScienceOn |
39 | Wynn RL. Oral bisphosphonates and osteonecrosis of the jaw. Gen Dent 2007;55:8-10 PUBMED |
40 | Marx RE, Cillo JE, Jr., Ulloa JJ. Oral bisphosphonateinduced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007;65:2397-2410 DOI ScienceOn |
41 | Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-1491 |
42 | Rinchuse DJ, Sosovicka MF, Robison JM, Pendleton R. Orthodontic treatment of patients using bisphosphonates: a report of 2 cases. Am J Orthod Dentofacial Orthop 2007; 131 :321-326 DOI ScienceOn |
43 | Alakangas A, Selander K, Mulari M, et a!. Alendronate disturbs vesicular trafficking in osteoclasts. Calcif Tissue Int 2002;70:40-47 DOI ScienceOn |
44 | Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff S1. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-534 DOI ScienceOn |
45 | Brooks JK, Gilson AJ, Sindler AJ, et al. Osteonecrosis of the jaws associated with use of risedronate: report of 2 new cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 103 :780-786 DOI ScienceOn |
46 | Cartsos VM, Zhu S, Zavras AI. Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people. J Am Dent Assoc 2008; 139:23-30 DOI PUBMED |
47 | Green JR. Bisphosphonates: preclinical review. Oncologist 2004;9 Suppl 4:3-13 PUBMED |
48 | Sawatari Y, Marx RE. Bisphosphonates and bisphosphonate induced osteonecrosis. Oral Maxillofac Surg Clin North Am 2007;19:487-498, v-vi DOI ScienceOn |
49 | Reid lR, Bolland M J, Grey AB. Is bisphosphonatcassociated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 2007;41 :318-320 DOI ScienceOn |
50 | Etminan M, Aminzadeh K, Matthew JR, Brophy JM. Use of oral bi;:.phosphonates and the risk of aseptic osteonecrosis: a nested case-control study. J Rheumatol 2008;35 :691-695 PUBMED |